Nanobiotix Files 6-K, Confirms 20-F Reporting

Ticker: NBTX · Form: 6-K · Filed: Oct 24, 2025 · CIK: 1760854

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer, sec-reporting

TL;DR

Nanobiotix filed a 6-K, confirming they'll use Form 20-F for annual reports.

AI Summary

Nanobiotix S.A. filed a Form 6-K on October 24, 2025, reporting its status as a foreign private issuer. The company, incorporated in France with its principal executive office in Paris, is subject to the 1934 Securities Exchange Act. This filing indicates Nanobiotix will file its annual reports under Form 20-F.

Why It Matters

This filing is a routine regulatory update for foreign private issuers, confirming their reporting framework with the SEC, which is important for investors tracking compliance and disclosure standards.

Risk Assessment

Risk Level: low — This is a standard regulatory filing for a foreign private issuer and does not contain new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC that the issuer makes or is required to make public pursuant to the laws of its home country or that it furnishes or is required to furnish to its security holders.

Which annual report form will Nanobiotix S.A. file?

Nanobiotix S.A. will file its annual reports under cover of Form 20-F.

What is the principal executive office of Nanobiotix S.A.?

The principal executive office of Nanobiotix S.A. is located at 60 Rue de Wattignies, 75012 Paris, France.

What is the Commission File Number for Nanobiotix S.A.?

The Commission File Number for Nanobiotix S.A. is 001-39777.

What is the SIC code for Nanobiotix S.A.?

The Standard Industrial Classification (SIC) code for Nanobiotix S.A. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-10-24 06:30:04

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: October 24, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing